Prospective study of apatinib combined with chemoradiotherapy for head and neck squamous cell carcinoma
10.3760/cma.j.cn113030-20210608-00219
- VernacularTitle:阿帕替尼联合放化疗治疗晚期头颈部鳞癌的前瞻性研究
- Author:
Mengmeng LI
1
;
Tingting LI
;
Feng CAI
;
Yajun ZHANG
;
Xianwen ZHANG
;
Jingjing LIU
;
Yufu ZHOU
;
Qian SUN
;
Gengming WANG
;
Rujun CHEN
;
Xin CHEN
;
Genlan ZHA
;
Hao JIANG
Author Information
1. 蚌埠医学院第一附属医院肿瘤放疗科，蚌埠 233004
- Keywords:
Apatinib;
Anti-angiogenesis;
Head and neck neoplasm/concurrent chemoradiotherapy
- From:
Chinese Journal of Radiation Oncology
2022;31(2):125-130
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of apatinib in combination with chemoradiotherapy for head and neck squamous cell carcinoma (HNSCC).Methods:37 patients orally received apatinib at 250 mg/d during concurrent chemoradiotherapy until completion of radiotherapy, complete remission assessed by imaging examination, the onset of unacceptable toxicity or death. Baseline characteristics, objective response rates (ORR) and adverse events were assessed in all enrolled patients with complete baseline and safety data. Progression-free survival (PFS) and overall survival (OS) were calculated by Kaplan-Meier method. Prognostic factors were statistically identified using Cox regression models.Results:The ORR was 85%(95% CI: 72%-98%). The median PFS was 17.9 months and the 2-year OS rate was 62%(95% CI: 48%-80%). Ineffective short-term efficacy ( HR=0.035, 995% CI: 0.02-0.652, P=0.025) was an independent risk factor for poor OS. In addition, ineffective short-term efficacy ( HR=0.104, 95% CI: 0.017-0.633, P=0.014) and lymphocytopenia ( HR=17.539, 95% CI: 2.040-150.779, P=0.009) were independent risk factors for poor PFS. Common adverse events (>60%) included lymphocytopenia (76%), leukopenia (68%) and irradiation-induced mucosal injury (65%). The most common treatment-associated grade 3 adverse event was lymphopenia (49%). Conclusions:Apatinib combined with chemoradiotherapy yield significant anti-tumor activity for HNSCC with controllable toxicity. For patients with advanced HNSCC, short-term efficacy and lymphocytopenia may be potential predictors for clinical efficacy of apatinib combined with chemoradiotherapy.
